To: Board of Supervisors
From: Dr. Grant Colfax, Health Services Director
Report Title: Amendment to Purchase Order with Hologic Sales and Service, LLC
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute on behalf of the Health Services Director, an amendment to purchase order #29236 with Hologic Sales and Service, LLC, to increase the payment limit by $1,000,000 to an amount not to exceed $2,000,000 to provide additional laboratory testing reagents, kits, and supplies for influenza, Candida auris screening, Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), and Hepatitis C (HCV) viral loads at the Contra Costa Public Health Laboratory with no change to the term ending January 16, 2027.
FISCAL IMPACT:
Approval of this action will result in additional expenditures of up to $1,000,000 and will be funded by Hospital Enterprise Fund I revenues.
BACKGROUND:
The Contra Costa Public Health Laboratory has used equipment and reagents from Hologic Sales and Service, LLC formerly known as Hologic, Inc. since 2015. Routine diagnostic testing is performed on Hologic instrumentation daily and allows for high-volume screening. The prior blanket purchase order (PO) approved for period extension requires additional funds to continue diagnostic testing through January 2027. Additionally, the laboratory strives to ensure funds are available on POs for unexpected public health emergencies. Hologic Panther is one of the instrument platforms that the Centers for Disease Control and Prevention (CDC) has considered as appropriate, in their Nucleic Acid Amplification Platform Investigative Summary Report, for future public health testing responses, including surveillance and diagnostic needs using CDC-designed tests.
On October 24, 2023, the Board of Supervisors approved agenda item C.29 to execute purchase order #29236 with Hologic Sales and Service, LLC and related agreement amendment for the purchase of testing reagents, kits and related laboratory testing supplies for the period from October 1, 2023 through September 30, 2024. The agreement amendment effective September 5, 2023 automatically renews on an annual basis unless either party provides written notice of its intent not to renew.
On September 24, 2024, the Board of Supervisors approved agenda item C.67 to execute an amendment to purchase order #29236 with Hologic Sales and Service, LLC to extend the term through September 30, 2025 with no change to the original payment limit of $1,000,000 for the purchase of laboratory testing supplies, reagents and kits.
On April 15, 2025, the Board of Supervisors approved agenda item C.54 to execute an amendment to purchase order #29236 to extend the term through January 16, 2026, with no change to the payment limit of $1,000,000, and execute Amendment No. 5 to the Master Terms and Conditions Agreement to reduce the unit price of the HBV quantitative detection assay.
On April 27, 2026, the Board of Supervisors approved agenda item C.60 to execute an amendment to purchase order #29236 to extend the term through January 16, 2027, with no change to the payment limit of $1,000,000.
Due to an increase in the variety and amount of testing performed on the Hologic instruments, the laboratory team has determined that an expanded purchase order is necessary. This adjustment in purchasing has resulted in a delay in processing the extension request. On March 23, 2026 the Purchasing Agent approved the continued use of Hologic Sales and Service, LLC.
Approval of this action will allow for the continued purchase of test menu reagents and kits for the detection of Candida auris, Herpes Simplex Virus (HSV) 1 & 2, HIV viral load, HCV viral load, HBV viral load testing, and Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV-2)/Influenza/Respiratory Syncytial Virus (RSV) screening at the Contra Costa County Public Health Laboratory through January 16, 2027
CONSEQUENCE OF NEGATIVE ACTION:
If this action is not approved, the Contra Costa Public Health Laboratory will not be able to purchase the test reagents needed to perform regular screening and viral load testing. This would have a significant impact on the laboratory’s operations.